YM 58483是一种吡唑衍生的CRAC通道抑制剂，能抑制Ca2+信号，IC50值为100nM。
Cas No.:223499-30-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
YM 58483 is a pyrazole-derived inhibitor of CRAC channels that inhibits Ca2+ signals with an IC50 value of 100nM [1]. YM 58483 suppresses the CRAC, TRPC3, and TRPC5 channels and facilitates the TRPM4 channel, reducing cytokine production and NFAT dephosphorylation [2]. YM 58483 has been widely used as a potent analgesic to alleviate thermal hyperalgesia and mechanical hyperalgesia in mice[3].
In vitro, YM 58483 treatment for 48 hours significantly inhibited the production of IL-5 and IL-13 in human peripheral blood cells induced by phytohemagglutinin-P (PHA), with IC50 values of 125nM and 148nM, respectively[4]. The pretreatment of YM 58483 for 1 hour inhibited the production of IL-4 and IL-5 in conalbumin-stimulated D10.G4.1 cells, with IC50 values of 200nM and 180nM, respectively[5]. Treatment with 30µM YM 58483 for 24 hours significantly reduced the proliferation of glioblastoma stem cells (GSC) and decreased the expression of SOX2[6].
In vivo, YM 58483 treatment via oral administration at a dose of 30mg/kg/day for 10 consecutive days significantly inhibited the activity of donor anti-host cytotoxic T lymphocytes (CTL) and the production of IFN-γ, and reduced the number of donor T cells in the spleen within the mouse model of graft-versus-host disease (GVHD)[7]. Oral administration of 10mg/kg dose of YM 58483 daily for 10 consecutive days significantly inhibited the development of collagen-induced paw edema in mice, alleviated joint damage in mice, and improved spontaneous movement defects[8].
References:
[1] Parekh A B. Store-operated CRAC channels: function in health and disease[J]. Nature reviews Drug discovery, 2010, 9(5): 399-410.
[2] Rubaiy H N. ORAI calcium channels: regulation, function, pharmacology, and therapeutic targets[J]. Pharmaceuticals, 2023, 16(2): 162.
[3] Gao R, Gao X, Xia J, et al. Potent analgesic effects of a store-operated calcium channel inhibitor[J]. PAIN®, 2013, 154(10): 2034-2044.
[4] Ohga K, Takezawa R, Yoshino T, et al. The suppressive effects of YM-58483/BTP-2, a store-operated Ca2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo[J]. Pulmonary pharmacology & therapeutics, 2008, 21(2): 360-369.
[5] Yoshino T, Ishikawa J, Ohga K, et al. YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models[J]. European journal of pharmacology, 2007, 560(2-3): 225-233.
[6] Terrié E, Déliot N, Benzidane Y, et al. Store-operated calcium channels control proliferation and self-renewal of cancer stem cells from glioblastoma[J]. Cancers, 2021, 13(14): 3428.
[7] Ohga K, Takezawa R, Arakida Y, et al. Characterization of YM-58483/BTP2, a novel store-operated Ca2+ entry blocker, on T cell-mediated immune responses in vivo[J]. International immunopharmacology, 2008, 8(13-14): 1787-1792.
[8] Gao X H, Gao R, Tian Y Z, et al. A store‐operated calcium channel inhibitor attenuates collagen‐induced arthritis[J]. British journal of pharmacology, 2015, 172(12): 2991-3002.
YM 58483是一种吡唑衍生的CRAC通道抑制剂，能抑制Ca2+信号，IC50值为100nM[1]。YM 58483可抑制CRAC、TRPC3和TRPC5通道，并促进TRPM4通道，从而减少细胞因子的产生和NFAT的去磷酸化[2]。YM 58483已被广泛用作一种强效镇痛剂，以减轻小鼠的热痛觉过敏和机械性痛觉过敏[3]。
在体外，YM 58483处理人外周血细胞48小时，显著抑制了植物phytohemagglutinin-P(PHA)诱导的IL-5和IL-13的产生，IC50值分别为125nM和148nM[4]。YM 58483预处理1小时可抑制conalbumin刺激的D10.G4.1细胞中IL-4和IL-5的产生，IC50值分别为200nM和180nM[5]。30µM的YM 58483处理胶质母细胞瘤干细胞(GSC)24小时，显著降低了细胞增殖和SOX2的表达[6]。
在体内，在移植物抗宿主病小鼠模型(GVHD)中，连续10天口服30mg/kg/day剂量的YM 58483，显著抑制了供体抗宿主细胞毒性T淋巴细胞(CTL)的活性和IFN-γ的产生，并减少了脾脏中供体T细胞的数量[7]。连续10天每日口服10mg/kg剂量的YM 58483，显著抑制了胶原诱导的小鼠爪水肿的发展，减轻了小鼠的关节损伤，并改善了自发性运动缺陷[8]。
| Cell experiment [1]: | |
Cell lines | Patient-derived glioblastoma stem cells (GSCs) |
Preparation Method | GSCs were grown in DMEM/HAM-F12 medium with 2mM glutamine, 10% (v/v) fetal bovine serum (FBS), 2μg/ml heparin, 20ng/ml EGF and 25ng/ml bFGF, 100U/ml penicillin and 100μg/ml streptomycin at 37°C in 5% CO2/atmosphere. GSCs (3×104 cells) were seeded on 96-well plates, incubated for 24h, and then treated with different concentrations of YM 58483 (0.1, 1, 10, 20, and 30µM) at 37°C. After 24h, cell viability was measured. |
Reaction Conditions | 0.1, 1, 10, 20, and 30µM; 24h |
Applications | YM 58483 treatment significantly reduced the cell viability of GSCs in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male DBA/1 mice |
Preparation Method | Male DBA/1 mice (7 weeks old) were housed singly in a standard environment with food and water ad libitum. Mice were acclimated for a week before starting the experiment. 100μg chicken type II collagen (CII) was mixed with 100μl complete Freund's adjuvant and injected i.d. on day 0 at the base of the tail. On day 21, a booster injection of 100μg chicken CII in 100μl of PBS was administered (i.p.). YM 58483 (10mg/kg) or vehicle was administered daily from days 28 to 37. The effect of YM 58483 on paw oedema in mice was measured. |
Dosage form | 10mg/kg/day for 10 days; i.p. |
Applications | YM 58483 treatment significantly reduced the CII-induced paw oedema in mice. |
References: | |
| Cas No. | 223499-30-7 | SDF | |
| 别名 | BTP2 | ||
| 化学名 | N-(4-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide | ||
| Canonical SMILES | FC(F)(C1=CC(C(F)(F)F)=NN1C(C=C2)=CC=C2NC(C3=C(C)N=NS3)=O)F | ||
| 分子式 | C15H9F6N5OS | 分子量 | 421.32 |
| 溶解度 | ≥ 50 mg/mL in EtOH, ≥ 90 mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3735 mL | 11.8675 mL | 23.7349 mL |
| 5 mM | 474.7 μL | 2.3735 mL | 4.747 mL |
| 10 mM | 237.3 μL | 1.1867 mL | 2.3735 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet